Reata Pharmaceuticals, Inc. (NASDAQ:RETA)‘s stock had its “buy” rating reiterated by research analysts at Robert W. Baird in a research report issued on Tuesday. They presently have a $47.00 price objective on the stock. Robert W. Baird’s price objective points to a potential upside of 43.38% from the stock’s current price.

Several other equities analysts have also issued reports on the company. Zacks Investment Research lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Piper Jaffray Companies upped their target price on Reata Pharmaceuticals from $53.00 to $60.00 and gave the company a “buy” rating in a report on Monday, July 24th. Citigroup Inc. reaffirmed a “buy” rating and issued a $87.00 target price (up from $39.00) on shares of Reata Pharmaceuticals in a report on Tuesday, July 25th. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $61.00 target price (up from $55.00) on shares of Reata Pharmaceuticals in a report on Wednesday, July 26th. Finally, Jefferies Group LLC started coverage on Reata Pharmaceuticals in a report on Wednesday, August 30th. They issued a “buy” rating and a $44.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. Reata Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $54.71.

Reata Pharmaceuticals (NASDAQ:RETA) traded up 0.52% during mid-day trading on Tuesday, hitting $32.78. The stock had a trading volume of 76,892 shares. The firm’s 50-day moving average price is $31.13 and its 200-day moving average price is $28.00. Reata Pharmaceuticals has a 1-year low of $18.51 and a 1-year high of $41.60. The stock’s market cap is $855.66 million.

COPYRIGHT VIOLATION NOTICE: “Reata Pharmaceuticals, Inc. (RETA) Rating Reiterated by Robert W. Baird” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/10/24/reata-pharmaceuticals-inc-reta-rating-reiterated-by-robert-w-baird.html.

In other news, Director James Edward Bass acquired 8,064 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were acquired at an average price of $31.00 per share, for a total transaction of $249,984.00. Following the completion of the purchase, the director now owns 67,411 shares in the company, valued at $2,089,741. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 62.40% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently bought and sold shares of the stock. Nationwide Fund Advisors lifted its stake in Reata Pharmaceuticals by 38.3% in the third quarter. Nationwide Fund Advisors now owns 6,040 shares of the company’s stock valued at $188,000 after purchasing an additional 1,672 shares during the last quarter. P.A.W. Capital Corp purchased a new position in Reata Pharmaceuticals in the third quarter valued at approximately $933,000. California State Teachers Retirement System lifted its stake in Reata Pharmaceuticals by 20.8% in the second quarter. California State Teachers Retirement System now owns 15,125 shares of the company’s stock valued at $479,000 after purchasing an additional 2,600 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in Reata Pharmaceuticals by 102.4% in the second quarter. The Manufacturers Life Insurance Company now owns 7,343 shares of the company’s stock valued at $233,000 after purchasing an additional 3,715 shares during the last quarter. Finally, State Street Corp lifted its stake in Reata Pharmaceuticals by 4.9% in the second quarter. State Street Corp now owns 108,212 shares of the company’s stock valued at $3,422,000 after purchasing an additional 5,094 shares during the last quarter. Institutional investors and hedge funds own 15.56% of the company’s stock.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Analyst Recommendations for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.